person · Reporting owner

Blumenkranz Mark S.

Disclosed activity across 4 companies

Tapewire entity: 24035
SEC CIK: 0001614869

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Annexon, Inc.ANNX · Entity 5011	Director	August 10, 2026	August 12, 2026
KALA BIO, Inc.KALA · Entity 7964	Director	June 11, 2024	June 13, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Annexon, Inc.

Report date August 10, 2026 · Filed August 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.39 · Expires 2036-08-10	Direct	175,000	Reported balance After 2026-08-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-08-10 · Grant · Acquired 175,000 · Balance 175,000 F1: 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service as a director on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service as a director on each such vesting date.

KALA BIO, Inc.

Report date June 11, 2024 · Filed June 13, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,091	Reported balance After 2024-06-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-06-11 · Grant · Acquired 1,400 · Balance 13,091 F1: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024. F2: Includes 6,615 unvested RSUs.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.18 · Expires 2034-06-10	Direct	3,150	Reported balance After 2024-06-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-06-11 · Grant · Acquired 3,150 · Balance 3,150 F5: This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024.
Common StockSEC Table I · non-derivative	IndirectSee footnote	168,454	Reported balance Holding disclosure · report date 2024-06-11 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 168,454 F3: These securities are held directly by Lagunita Biosciences, LLC ("Lagunita"). The reporting person is a managing partner of Lagunita and may be deemed to have beneficial ownership over the Lagunita Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,276	Reported balance Holding disclosure · report date 2024-06-11 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,276 F4: These securities are held directly by Garland Investments, L.P. ("Garland"). The reporting person is a managing partner of Garland and may be deemed to have beneficial ownership over the Garland Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024.

F2: Includes 6,615 unvested RSUs.

F3: These securities are held directly by Lagunita Biosciences, LLC ("Lagunita"). The reporting person is a managing partner of Lagunita and may be deemed to have beneficial ownership over the Lagunita Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4: These securities are held directly by Garland Investments, L.P. ("Garland"). The reporting person is a managing partner of Garland and may be deemed to have beneficial ownership over the Garland Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F5: This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

1Life Healthcare Inc

Report date February 22, 2023 · Filed February 24, 2023

Section 16 reporting ended · disclosed 2023-02-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-02-22 transaction · row 1 1 source row Row 1 · 2023-02-22 · Disposition to issuer · Disposed 4,534 · Balance 0 F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 20, 2022, by and among Issuer, Amazon.com, Inc. ("Parent") and Negroni Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on February 22, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, par value $0.001 per share ("Shares") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $18.00 in cash, without interest (the "Merger Consideration").
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.56 · Expires 2029-11-20	Direct	Reported balance After 2023-02-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-02-22 · Disposition to issuer · Disposed 10,381 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding option ("Option") to purchase Shares granted under any of the Issuer's 2007 Equity Incentive Plan, 2017 Equity Incentive Plan, 2020 Equity Incentive Plan and the Iora Third Amended and Restated 2011 Equity Incentive Plan (collective, the "Issuer Stock Plans") or portion thereof that was vested or became vested as of the Effective Time, and had an exercise price per Share that is less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such Option and (ii) the aggregate number of Shares issuable upon exercise of such Option or portion thereof, subject to any required withholding of taxes. F3: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years, subject to reporting person's continuous service as of each such date. At the Effective Time, any unvested shares subject to the option was accelerated in full.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.00 · Expires 2030-05-13	Direct	Reported balance After 2023-02-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-02-22 · Disposition to issuer · Disposed 5,294 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each Option, whether vested or unvested, that has an exercise price per Share that is greater than the Merger Consideration was canceled without the payment of consideration. F5: The shares subject to the option are fully vested and immediately exercisable.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-02-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-02-22 · Disposition to issuer · Disposed 20,728 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. RSUs convert into the issuer's common stock on a one-for-one basis. F7: The RSUs vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant. At the Effective Time, each outstanding RSU that was unvested was accelerated in full and was automatically converted in to the right to receive the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 20, 2022, by and among Issuer, Amazon.com, Inc. ("Parent") and Negroni Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on February 22, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, par value $0.001 per share ("Shares") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $18.00 in cash, without interest (the "Merger Consideration").

F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding option ("Option") to purchase Shares granted under any of the Issuer's 2007 Equity Incentive Plan, 2017 Equity Incentive Plan, 2020 Equity Incentive Plan and the Iora Third Amended and Restated 2011 Equity Incentive Plan (collective, the "Issuer Stock Plans") or portion thereof that was vested or became vested as of the Effective Time, and had an exercise price per Share that is less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such Option and (ii) the aggregate number of Shares issuable upon exercise of such Option or portion thereof, subject to any required withholding of taxes.

F3: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years, subject to reporting person's continuous service as of each such date. At the Effective Time, any unvested shares subject to the option was accelerated in full.

F4: Pursuant to the Merger Agreement, at the Effective Time, each Option, whether vested or unvested, that has an exercise price per Share that is greater than the Merger Consideration was canceled without the payment of consideration.

F5: The shares subject to the option are fully vested and immediately exercisable.

F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. RSUs convert into the issuer's common stock on a one-for-one basis.

F7: The RSUs vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant. At the Effective Time, each outstanding RSU that was unvested was accelerated in full and was automatically converted in to the right to receive the Merger Consideration.

IVERIC bio, Inc.

Report date July 11, 2023 · Filed July 13, 2023

Section 16 reporting ended · disclosed 2023-07-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-07-11 transaction · row 1 1 source row Row 1 · 2023-07-11 · Disposition to issuer · Disposed 32,088 · Balance 0 F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-07-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-07-11 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.48 · Expires 2030-07-14	Direct	Reported balance After 2023-07-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-07-11 · Disposition to issuer · Disposed 31,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.82 · Expires 2031-05-18	Direct	Reported balance After 2023-07-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-07-11 · Disposition to issuer · Disposed 15,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.94 · Expires 2032-05-11	Direct	Reported balance After 2023-07-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-07-11 · Disposition to issuer · Disposed 23,186 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.

F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.

F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 14, 2020 Filed May 18, 2020 17:44 UTC	1Life Healthcare Inc ONEM · Entity 116460	GrantStock Option (Right to Buy) · Derivative	5,294	$0.00 Strike: $29.00	$0.00	Disclosure SEC source: 0001209191-20-030189 · doc4.xml · derivative · entry 1 Blumenkranz Mark S. · CIK 0001614869 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,294 Underlying: Common Stock · 5,294 shares Expires 2030-05-13 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) the date of the Issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the Reporting Person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.